Posted by Michael Wonder on 08 Apr 2024
Phanes Therapeutics' PT217 granted fast track designation by the FDA
8 April 2024 - Phanes Therapeutics announced today that the US FDA has granted fast track designation to PT217 for the treatment of patients with extensive-stage small cell lung cancer with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.
PT217 was also granted orphan drug designation for the treatment of small cell lung cancer by the FDA in 2022.
